ARCH Venture Partners — 2017 Investments
5 investments dated 2017 · listed companies and verified rows first · show all
Clinical-stage biopharmaceutical company focused on discovery and development of innovative medicines for serious diseases by targeting the Transforming Growth Factor Beta pathway.
BiotechCambridge, US
Alan Buckler(Executive Officer)Nagesh Mahanthappa(Executive Officer, Director)Timothy Springer(Director)David Hallal(Director)Michael Gilman(Director)Jeffrey Flier(Director)
Board seatKristina Burow· per SEC Form D · $47M raise · filed Jan 2018
HealthtechSeattle, US
Nathan Price(Director)Tim Kilgallon(Director)Clayton Lewis(Executive Officer, Director)
Board seatRobert Nelsen· per SEC Form D · $30M raise · filed Jun 2017
Research Triangle Park, US
Tracy Jackson(Executive Officer)John Dombrosky(Executive Officer)Joel Marcus(Director)Stephen Benkovic(Director)Paul Schimmel(Director)
Board seatKristina Burow· per SEC Form D · $10.5M raise · filed Mar 2017
BiotechWeslake Village, US
Dennis Fenton(Director)Bob More(Director)Diane Stroehmann(Executive Officer)Frederick C. Beddingfield III(Executive Officer, Director)Paul F. Lizzul(Executive Officer)Ric Peterson(Executive Officer)
Board seatRobert NelsenKristina Burow· per SEC Form D · $40.5M raise · filed May 2017
BiotechHayward, US
Jay Kouba(Executive Officer, Director)Thomas Erickson(Director)Doug Cameron(Director)
Board seatKristina Burow· per SEC Form D · $80K raise · filed Apr 2017
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.